Shots:
- GenScript will be responsible for all pre-clinical
pharmacy research and IND filling in Selecxine’s project which is based on cytokine-antibody
complexes - The company provided development solutions in
different hosts tailored to customers and provided the preparation and
purification solutions for the final complex,; further the project will test
and enhance the process development capability of GenScript CDMO team - SLC-3010 is a complex of IL-2 and anti-human
IL-2 antibody (TCB2) that selectively stimulates the anti-tumor immune response
and its efficacy for the removal of various types of tumor was thoroughly
demonstrated through various in vitro and in vivo experiments
Click here to read full press release/ article | Ref: PRNewswire | Image: Behance
